Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) rose more than 6% in the intraday period, Citi indicates that business operations have reached an inflection point, and the value of the ATTC platform will show

The Zhitong Finance App learned that Hehuang Pharmaceutical (00013) rose more than 6% in the intraday period. As of press release, it rose 3.92% to HK$22.28, with a turnover of HK$128 million.

According to the news, at the end of September, Chi-Med announced that AstraZeneca had submitted a marketing application for the US FDA for the treatment of locally advanced or metastatic non-small cell lung cancer patients with excessive MET expression or amplification during or after treatment with EGFR TKI. The SAFFRON global phase III study showed improvements in both progression-free survival and overall survival.

Citi released a research report saying that Hewang Pharmaceutical's business operations have seen an inflection point from innovation, clinical progress, and sales recovery. The bank believes that as data is disclosed or transactions continue to be reached, the value of the ATTC platform will become more specific. At the same time, it is expected that SAFFRON and SANOVO will bring positive readout data.